In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism

European Journal of Pharmacology
J F van der WerfJ Korf

Abstract

The accumulation and retention of radioactivity in rat brain were studied after intravenous injection of the dopamine (DA) agonist [3H]N-n-propylnorapomorphine ( [3H]NPA). Dose-dependent saturable accumulation of label was found in the striatum, nucleus accumbens and olfactory tubercle. DA agonists (apomorphine, N,N-dipropyl-5,6-ADTN) and antagonists (haloperidol, cis-flupenthixol) prevented this accumulation. Enhanced accumulation of radioactivity in the striatum was found after 6-OHDA lesions and short- and long-term treatment with reserpine. These results are an indication of specific NPA binding to presumably postsynaptically situated DA receptors. One hour after administration of the drug, the effect of NPA on striatal DA metabolism was not correlated with receptor saturation. Maximal numbers of in vivo NPA binding sites (about 30 and 22 pmol . g-1) in striatal tissue were calculated from independent measurements at 15 and 60 min after NPA injection. Regional distribution of radioactivity after a tracer dose of [3H]NPA was assessed in 35 brain areas and parts of the spinal cord. In addition to the already mentioned DA-rich areas receptor-specific NPA binding was also found in several other brain parts.

References

Apr 1, 1979·European Journal of Pharmacology·J McCulloch, G Teasdale
Jul 1, 1979·European Journal of Pharmacology·M Quik, L L Iversen
Jul 1, 1979·European Journal of Pharmacology·I CreeseF Lopez
Jun 1, 1976·European Journal of Pharmacology·B H Westerink, J Korf
Jul 1, 1981·Journal of Neurochemistry·P DemengeC Feuerstein
Dec 5, 1980·European Journal of Pharmacology·S BischoffJ Krauss
Sep 1, 1980·The International Journal of Applied Radiation and Isotopes·C CrouzelD Comar

❮ Previous
Next ❯

Citations

Jun 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·M G FeenstraA S Horn
Jan 1, 1991·Journal of Neural Transmission. General Section·O InoueB Langstrom
Nov 19, 1986·European Journal of Pharmacology·G BianchiS Garattini
Jun 1, 1995·Pharmacology, Biochemistry, and Behavior·H J CoppensJ Korf
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M LaruelleR B Innis
Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LaruelleR B Innis
Feb 1, 1987·Journal of Neurochemistry·O Gredal, M Nielsen
Apr 26, 2002·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Paul CummingAlbert Gjedde
Mar 21, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M Laruelle
Feb 10, 2000·Journal of Psychopharmacology·M Laruelle, A Abi-Dargham
Oct 1, 1984·Journal of Neurochemistry·J Korf, F Postema
May 27, 2014·International Journal of Molecular Sciences·Nicola Pacini, Fabio Borziani
Nov 5, 2019·Frontiers in Molecular Neuroscience·Matthieu ColomLuc Zimmer
Jul 10, 2002·Annals of the New York Academy of Sciences·Paul CummingAlbert Gjedde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here